Trading Places: The substantial holders buying and selling in the last week
Link copied to
Trading Places is Stockhead’s weekly recap of substantial holder movements focusing on fund managers.
Substantial shareholders are shareholders holding 5 per cent or more of a company’s shares and these can be directors, individual investors or institutional investors.
Shareholders are required to announce to the exchange when they cross above or below the 5 per cent threshold and any change in their holdings while they remain above 5 per cent.
Among Regal Funds Management’s buys this week were Richard White-backed, know-your-customer fintech Kyckr (ASX: KYK) and recent uranium convertee Lotus Resources (ASX: LOT) — formerly known as Hylea.
It already was a substantial holder in Kyckr, taing its stake to 6.14 per cent and became one of Lotus, buying a 5 per cent stake. But it only spent $600,000 and $280,000 respectively.
Since Stavely Minerals’ (ASX: SVY) 40 per cent copper hit there has been increased interest in companies with porphyry copper-gold projects. One is Carawine Resources (ASX: CWX) and private investment company Illewa increased its holdings to 9.05 per cent.
1832 Asset Management increased its holdings in Bellevue Gold (ASX: BGL) and Exore Resources (ASX: ERX) to 12.35 per cent and 7.65 per cent respectively.
Despite months of doom and gloom about the retail sector, AustralianSuper bought into Adairs (ASX: ADH), taking a 5.02 per cent.
As Athena Resources (ASX: AHN) seeks to re-enter the ASX, three substantial holders entered its list, one of which was Airlie Funds Management which took a 5.08 per cent stake.
IOOF bought a 5.37 per cent stake in RhinoMed (ASX: RNO) and increased its holdings in MetalsX (ASX: MLX) to 6.67 per cent.
New York based fund manager Emprey Asset Management bought a 8.94 per cent stake in Benetic Biopharma (ASX: BLT).
BVF Partners completely sold out of Opthea (ASX: OPT), parting with the last $20 million in stock. It owned up to 15 per cent of the company earlier this year but has been gradually selling.
The company nearly quadrupled in a matter of days after its main drug excelled at battling wet-AMD in its Phase-II clinical trial. But while it plans commercialisation, it is undertaking further trials and still waiting on the complete set of results of its successful clinical stint.
Amaysim (ASX: AYS) has more than halved in recent weeks after poor financial results and Fidelity has cut its ownership of the company to 7.5 per cent.
1832 Asset Management has done likewise with Africa-focused gold miner Cardinal Resources (ASX: CDV).
It’s been seven weeks since Roots Sustainable Agricultural Technologies (ASX: ROO) announced it was getting into the plant-based meat craze. While it initially surged, it has since retreated its pre-August levels. Private investor James Schwarz, through his company Jamber Investments, has cut his stake to only 3.2 per cent.